[1] Gupta S, Grant LM, Powers HR, Kimes KE, Hamdi A, Butterfield RJ, et al. Invasive Nocardia infections across distinct geographic regions, United States. Emerg Infect Dis 2023;29(12):2417 − 25. https://doi.org/10.3201/eid2912.230673.
[2] Parte AC, Sardà Carbasse J, Meier-Kolthoff JP, Reimer LC, Göker M. List of prokaryotic names with standing in nomenclature (LPSN) moves to the DSMZ. Int J Syst Evol Microbiol 2020;70(11):5607 − 12. https://doi.org/10.1099/ijsem.0.004332.
[3] Conville PS, Brown-Elliott BA, Smith T, Zelazny AM. The complexities of Nocardia taxonomy and identification. J Clin Microbiol 2018;56(1):e01419 − 17. https://doi.org/10.1128/JCM.01419-17.
[4] Han YG, Cheng MJ, Li Z, Chen HH, Xia S, Zhao Y, et al. Clinical characteristics and drug resistance of Nocardia in Henan, China, 2017-2023. Ann Clin Microbiol Antimicrob 2024;23(1):23. https://doi.org/10.1186/s12941-024-00677-4.
[5] Mehta HH, Shamoo Y. Pathogenic Nocardia: a diverse genus of emerging pathogens or just poorly recognized? PLoS Pathog 2020;16(3):e1008280. http://dx.doi.org/10.1371/journal.ppat.1008280.
[6] Huang L, Chen XC, Xu HP, Sun LY, Li C, Guo WC, et al. Clinical features, identification, antimicrobial resistance patterns of Nocardia species in China: 2009-2017. Diagn Microbiol Infect Dis 2019;94(2):165 − 72. https://doi.org/10.1016/j.diagmicrobio.2018.12.007.
[7] Tan YE, Chen SCA, Halliday CL. Antimicrobial susceptibility profiles and species distribution of medically relevant Nocardia species: results from a large tertiary laboratory in Australia. J Glob Antimicrob Resist 2020;20:110 − 7. https://doi.org/10.1016/j.jgar.2019.06.018.
[8] Rathish B, Zito PM. Nocardia. Treasure Island (FL): StatPearls. 2025. https://pubmed.ncbi.nlm.nih.gov/32809707/.
[9] Yang J, Ren HT, Wang J, Dong AY, Chen YL, Hu DX, et al. Clinical characteristics, susceptibility profiles, and treatment of nocardiosis: a multicenter retrospective study in 2015-2021. Int J Infect Dis 2023;130:136 − 43. https://doi.org/10.1016/j.ijid.2023.02.023.
[10] Lu SH, Qian ZW, Mou PP, Xie L. Clinical Nocardia species: identification, clinical characteristics, and antimicrobial susceptibility in Shandong, China. Bosn J Basic Med Sci 2020;20(4):531 − 8. https://doi.org/10.17305/bjbms.2020.4764.
[11] Duggal SD, Chugh TD. Nocardiosis: a neglected disease. Med Princ Pract 2020;29(6):514 − 23. https://doi.org/10.1159/000508717.
[12] Wang H, Zhu Y, Cui QZ, Wu WM, Li G, Chen DK, et al. Epidemiology and antimicrobial resistance profiles of the Nocardia species in China, 2009 to 2021. Microbiol Spectr 2022;10(2):e0156021 − 21. https://doi.org/10.1128/spectrum.01560-21.
[13] Zhao P, Zhang XJ, Du PC, Li GL, Li LX, Li ZJ. Susceptibility profiles of Nocardia spp. to antimicrobial and antituberculotic agents detected by a microplate Alamar Blue assay. Sci Rep 2017;7:43660. https://doi.org/10.1038/srep43660.
[14] Clinical and Laboratory Standards Institute. Performance standards for susceptibility testing of mycobacteria, Nocardia spp., and other aerobic actinomycetes. 2nd ed. Wayne: Clinical and Laboratory Standards Institute. 2023. https://clsi.org/shop/standards/m24s/.
[15] Yi ML, Wang LP, Xu WH, Sheng L, Jiang LH, Yang FZ, et al. Species distribution and antibiotic susceptibility of Nocardia isolates from Yantai, China. Infect Drug Resist 2019;12:3653 − 61. https://doi.org/10.2147/IDR.S232098.